Research Article
Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis
Figure 7
ECHO cardiographic representation of effects of aprepitant or fasudil treatment in viral-myocarditis. A representative ECHO reading from (a) uninfected mouse, (b) EMCV-infected mouse, (c) uninfected mouse with aprepitant pretreatment, (d) EMCV-infected mouse with aprepitant pretreatment, (e) uninfected mouse with aprepitant posttreatment, (f) EMCV-infected mouse with aprepitant posttreatment, (g) uninfected mouse with fasudil pretreatment, (h) EMCV-infected mouse with fasudil pretreatment, (i) uninfected mouse with fasudil posttreatment, and (j) EMCV-infected mouse with fasudil posttreatment.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |
(i) |
(j) |